A Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TNM005 and to Characterize the Pharmacodynamics of TNM005 and VARIZIG in Healthy Adult Volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TNM-005 (Primary) ; Varicella zoster immune globulin
Indications Varicella zoster virus infections
Focus Adverse reactions
Sponsors Trinomab Biotech

Most Recent Events

11 Oct 2023 New trial record
08 Oct 2023 According to a Trinomab Biotech media release, the company have successfully completed the enrollment and administration of the first subjects in this study.
08 Oct 2023 Status changed from not yet recruiting to recruiting, according to a Trinomab Biotech media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight